Low-dose Aspirin and Cancer Mortality: A Meta-analysis of Randomized Trials



      Low-dose aspirin is a common strategy for preventing cardiovascular disease and associated mortality. A recent individual patient data meta-analysis of 8 trials of low- and high-dose aspirin, with long-term follow-up, found important reductions in cancer mortality. We aimed to determine whether cancer mortality also is reduced by low-dose aspirin in the shorter term.


      We conducted a comprehensive search of 10 electronic databases up to December 2011. We conducted a meta-analysis using data from all randomized clinical trials evaluating low-dose (75-325 mg) daily aspirin. We extracted data on non-cardiovascular disease mortality and cancer mortality. We pooled studies using a random-effects model and conducted a meta-regression. We supplemented this with a cumulative meta-analysis and trial sequential monitoring analysis.


      Twenty-three randomized studies reported on nonvascular death. There were 944 nonvascular deaths of 41,398 (2.28%) patients receiving low-dose aspirin and 1074 nonvascular deaths of 41,470 (2.58%) patients not receiving aspirin therapy. The relative risk of nonvascular death was 0.88 (95% confidence interval [CI], 0.81-0.96, I2 = 0%). Eleven trials included data evaluating cancer mortality involving 16,066 patients. There were 162 of 7998 (2.02%) and 210 of 8068 (2.60%) cancer deaths among low-dose aspirin users versus non-aspirin users, respectively, reported over an average follow-up of 2.8 years. The relative risk of cancer mortality was 0.77 (95% CI, 0.63-0.95, I2 = 0%). Studies demonstrated a significant treatment effect after approximately 4 years of follow-up. The optimal information size analysis showed that a sufficient number of patients had been randomized to provide convincing evidence of a preventive role of low-dose aspirin in nonvascular deaths.


      Nonvascular deaths, including cancer deaths, are reduced with low-dose aspirin.


      To read this article in full you will need to make a payment


      Subscribe to The American Journal of Medicine
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Baigent C.
        • Blackwell L.
        • Collins R.
        • et al.
        Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials.
        Lancet. 2009; 373: 1849-1860
      1. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
        BMJ. 2002; 324: 71-86
        • Calvin A.D.
        • Aggarwal N.R.
        • Murad M.H.
        • et al.
        Aspirin for the primary prevention of cardiovascular events: a systematic review and meta-analysis comparing patients with and without diabetes.
        Diabetes Care. 2009; 32: 2300-2306
        • Burn J.
        • Gerdes A.M.
        • Macrae F.
        • et al.
        Long-term effect of aspirin on cancer risk in carriers of hereditary colorectal cancer: an analysis from the CAPP2 randomised controlled trial.
        Lancet. 2011; 378: 2081-2087
        • Rothwell P.
        • Fowkes F.G.
        • Belch J.F.
        • Ogawa H.
        • Warlow C.P.
        • Meade T.W.
        Effect of daily aspirin on long-term risk of death due to cancer: analysis of individual patient data from randomised trials.
        Lancet. 2011; 377: 31-41
        • Cuzick J.
        • Otto F.
        • Baron J.A.
        • et al.
        Aspirin and non-steroidal anti-inflammatory drugs for cancer prevention: an international consensus statement.
        Lancet Oncol. 2009; 10: 501-507
        • Elwood P.C.
        • Gallagher A.M.
        • Duthie G.G.
        • Mur L.A.J.
        • Morgan G.
        Aspirin, salicylates, and cancer.
        Lancet. 2009; 373: 1301-1309
        • Bosetti C.
        • Gallus S.
        • La Vecchia C.
        Aspirin and cancer risk: a summary review to 2007.
        Recent Results Cancer Res. 2009; 181: 231-251
        • Flossmann E.
        • Rothwell P.M.
        • British Doctors Aspirin Trial and the UK-TIA Aspirin Trial
        Effect of aspirin on long-term risk of colorectal cancer: consistent evidence from randomised and observational studies.
        Lancet. 2007; 369: 1603-1613
        • Rothwell P.M.
        • Wilson M.
        • Elwin C.-E.
        • et al.
        Long-term effect of aspirin on colorectal cancer incidence and mortality: 20-year follow-up of five randomised trials.
        Lancet. 2010; 376: 1741-1750
        • Cole B.F.
        • Logan R.F.
        • Halabi S.
        • et al.
        Aspirin for chemoprevention of colorectal adenomas: meta-analysis of the randomised trials.
        J Natl Cancer Inst. 2009; 101: 256-266
        • Bhatt D.L.
        • Scheiman J.
        • Abraham N.S.
        • et al.
        ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents.
        J Am Coll Cardiol. 2008; 52: 1502-1517
        • Berger J.S.
        • Krantz M.J.
        • Kittelson J.M.
        • Hiatt W.R.
        Aspirin for the prevention of cardiovascular events in patients with peripheral artery disease: a meta-analysis of randomized trials.
        JAMA. 2009; 301: 1909-1919
        • Wolff T.
        • Miller T.
        • Ko S.
        Aspirin for the primary prevention of cardiovascular events: an update of the evidence for the U.S. Preventive Services Task Force.
        Ann Intern Med. 2009; 150: 405-410
        • Steiner T.J.
        • Voelker M.
        Gastrointestinal tolerability of aspirin and the choice of over-the-counter analgesia for short-lasting acute pain.
        J Clin Pharm Ther. 2009; 34: 177-186
        • Serebruany V.L.
        • Malinin A.I.
        • Ferguson J.J.
        • Vahabi J.
        • Atar D.
        • Hennekens C.H.
        Bleeding risks of combination vs. single antiplatelet therapy: a meta-analysis of 18 randomized trials comprising 129,314 patients.
        Fundam Clin Pharmacol. 2008; 22: 315-321
        • Devereaux P.J.
        • Bhandary M.
        • Montori V.M.
        • et al.
        An observational study found that authors of randomized controlled trials frequently use concealment of randomization and blinding, despite the failure to report these methods.
        J Clin Epidemiol. 2004; 57: 1232-1236
        • Meade M.O.
        • Guyatt G.H.
        • Cook R.J.
        • et al.
        Agreement between alternative classifications of acute respiratory distress syndrome.
        Am J Respir Crit Care Med. 2001; 163: 490-493
        • McAlister F.A.
        • Straus S.E.
        • Guyatt G.H.
        • Haynes R.B.
        Users' guides to the medical literature: XX. Integrating research evidence with the care of the individual patient. Evidence-Based Medicine Working Group.
        JAMA. 2000; 283: 2829-2836
        • Fleiss J.L.
        The statistical basis of meta-analysis.
        Stat Methods Med Res. 1993; 2: 121-145
        • DerSimonian R.
        Laird N Meta-analysis in clinical trials.
        Control Clin Trials. 1986; 7: 177-188
        • Higgins J.P.
        • Thompson S.G.
        Quantifying heterogeneity in a meta-analysis.
        Stat Med. 2002; 21: 1539-1558
        • Thorlund K.
        • Devereaux P.J.
        • Wetterslev J.
        • et al.
        Can trial sequential monitoring boundaries reduce spurious inferences from meta-analyses?.
        Int J Epidemiol. 2009; 38: 276-286
        • Laffort P.
        • Roudaut R.
        • Roques X.
        • et al.
        Early and long-term (one-year) effects of the association of aspirin and oral anticoagulant on thrombi and morbidity after replacement of the mitral valve with the St. Jude Medical prosthesis: a clinical and transesophageal echocardiographic study.
        J Am Coll Cardiol. 2000; 35: 739-746
        • Cote R.
        • Battista R.N.
        • Abrahamowicz M.
        • Langlois Y.
        • Bourque F.
        • Mackey A.
        Lack of effect of aspirin in asymptomatic patients with carotid bruits and substantial carotid narrowing.
        Ann Intern Med. 1995; 123: 649-655
      2. United Kingdom Transient Ischaemic Attack (UK-TIA) aspirin trial: interim results.
        Br Med J (Clin Res Ed). 1988; 296: 316-320
        • Richard E.
        • Kuiper R.
        • Dijkgraaf M.G.
        • Van Gool W.A.
        Vascular care in patients with Alzheimer's disease with cerebrovascular lesions—a randomized clinical trial.
        J Am Geriatr Soc. 2009; 57: 797-805
        • Ogawa H.
        • Nakayama M.
        • Morimoto T.
        • et al.
        Low-dose aspirin for primary prevention of atherosclerotic events in patients with type 2 diabetes: a randomized controlled trial.
        JAMA. 2008; 300: 2134-2141
        • Giannarini G.
        • Mogorovich A.
        • Valent F.
        • et al.
        Continuing or discontinuing low-dose aspirin before transrectal prostate biopsy: results of a prospective randomized trial.
        Urology. 2007; 70: 501-505
      3. Final report on the aspirin component of the ongoing Physicians' Health Study.
        N Engl J Med. 1989; 321: 129-135
        • Landolfi R.
        • Marchioli R.
        • Kutti J.
        • et al.
        Efficacy and safety of low-dose aspirin in polycythemia vera.
        N Engl J Med. 2004; 350: 114-124
      4. Thrombosis Prevention Trial: randomised trial of low-intensity oral anticoagulation with warfarin and low-dose aspirin in the primary prevention of ischaemic heart disease in men at increased risk.
        Lancet. 1998; 351: 233-241
      5. Adjusted-dose warfarin versus low-intensity, fixed-dose warfarin plus aspirin for high-risk patients with atrial fibrillation: Stroke Prevention in Atrial Fibrillation III randomised clinical trial.
        Lancet. 1996; 348: 633-638
        • Catalano M.
        • Born G.
        • Peto R.
        Prevention of serious vascular events by aspirin amongst patients with peripheral arterial disease: randomized, double-blind trial.
        J Intern Med. 2007; 261: 276-284
        • Hansson L.
        • Zanchetti A.
        • Carruthers S.G.
        • et al.
        Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial.
        Lancet. 1998; 351: 1755-1762
      6. Prevention of pulmonary embolism and deep vein thrombosis with low dose aspirin: Pulmonary Embolism Prevention (PEP) trial.
        Lancet. 2000; 355: 1295-1302
        • Turpie A.G.
        • Gent M.
        • Laupacis A.
        • et al.
        A comparison of aspirin with placebo in patients treated with warfarin after heart-valve replacement.
        N Engl J Med. 1993; 329: 524-529
        • Lechat P.
        • Lardoux H.
        • Mallet A.
        • et al.
        Anticoagulant (fluindione)-aspirin combination in patients with high-risk atrial fibrillation.
        Cerebrovasc Dis. 2001; 12: 245-252
      7. Swedish Aspirin Low-Dose Trial (SALT) of 75 mg aspirin as secondary prophylaxis after cerebrovascular ischaemic events.
        Lancet. 1991; 338: 1345-1349
        • Lewis Jr, H.D.
        • Davis J.W.
        • Archibald D.G.
        • et al.
        Protective effects of aspirin against acute myocardial infarction and death in men with unstable angina.
        N Engl J Med. 1983; 309: 396-403
        • Casais P.
        • Meschengieser S.S.
        • Sanchez Luceros A.G.
        • Bermejo E.I.
        • Lazzari M.A.
        Effect of low-dose aspirin on the international normalized ratio variability in patients with mechanical heart valve prostheses.
        Pathophysiol Haemost Thromb. 2002; 32: 155-157
        • de Gaetano G.
        Low-dose aspirin and vitamin E in people at cardiovascular risk: a randomised trial in general practice.
        Lancet. 2001; 357: 89-95
        • Belch J.
        • MacCuish A.
        • Campbell I.
        • et al.
        The Prevention Of Progression of Arterial Disease And Diabetes (POPADAD) trial: factorial randomised placebo controlled trial of aspirin and antioxidants in patients with diabetes and asymptomatic peripheral arterial disease.
        BMJ. 2008; 337: a1840
        • Petersen P.
        • Boysen G.
        • Godtfredsen J.
        • Andersen E.D.
        • Andersen B.
        Placebo-controlled, randomised trial of warfarin and aspirin for prevention of thromboembolic complications in chronic atrial fibrillation.
        Lancet. 1989; 1: 175-179
        • Juul-Moller S.
        • Edvardsson N.
        • Jahnmatz B.
        • Rosen A.
        • Sorensen S.
        • Omblus R.
        Double-blind trial of aspirin in primary prevention of myocardial infarction in patients with stable chronic angina pectoris.
        Lancet. 1992; 340: 1421-1425
      8. Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor stroke.
        Lancet. 1993; 342: 1255-1262
        • Lanas A.
        • Wu P.
        • Medin J.
        • Mills E.J.
        Low doses of acetylsalicylic acid increase risk of gastrointestinal bleeding in a meta-analysis.
        Clin Gastroenterol Hepatol. 2011; 9: 762-768 e6
        • Ruschoff J.
        • Wallinger S.
        • Dietmaier W.
        • et al.
        Aspirin suppresses mutator phenotype associated with hereditary nonpolyposis colorectal cancer by genetic selection.
        Proc Natl Acad Sci U S A. 1998; 95: 11301-11306
        • McIlhatton M.A.
        • Tyler J.
        • Burkholder S.
        • et al.
        Nitric oxide-donating aspirin derivatives suppress microsatellite instability in mismatch repair-deficient and hereditary nonpolyposis colorectal cancer cells.
        Cancer Res. 2007; 67: 10966-10975
        • Hernandez-Diaz S.
        • Garcia Rodriguez L.A.
        Cardioprotective aspirin users and their excess risk of upper gastrointestinal complications.
        BMC Med. 2006; 4: 22
        • Bhatt D.L.
        • Cryer B.L.
        • Contant C.F.
        • et al.
        Clopidogrel with or without omeprazole in coronary artery disease.
        N Engl J Med. 2010; 363: 1909-1917
        • Leontiadis G.I.
        • Howden C.W.
        The role of proton pump inhibitors in the management of upper gastrointestinal bleeding.
        Gastroenterol Clin North Am. 2009; 38: 199-213
        • Yusuf S.
        • Pais P.
        • Afzal R.
        • et al.
        Effects of a polypill (Polycap) on risk factors in middle-aged individuals without cardiovascular disease (TIPS): a phase II, double-blind, randomised trial.
        Lancet. 2009; 373: 1341-1351
        • Yusuf S.
        Two decades of progress in preventing vascular disease.
        Lancet. 2002; 360: 2-3

      Linked Article

      • Dietary Fortification of Aspirin: A Novel Modality for Cancer Prevention
        The American Journal of MedicineVol. 126Issue 2
        • Preview
          Two important meta-analyses recently established the definitive additional benefit of long-term use of aspirin in the prevention of cancer development and risk of death.1,2 The extended use of aspirin has shown reductions in cancer incidence and mortality with its low case-fatality (decreasing metastases), which add to the case for daily aspirin as a potential chemopreventive agent against cancers.3,4
        • Full-Text
        • PDF
      • Aspirin-Associated Iron Loss: An Anticancer Mechanism Even in the Short Term?
        The American Journal of MedicineVol. 126Issue 2
        • Preview
          Mills et al1 demonstrated that the benefits of low-dose aspirin on cancer mortality protection seem to begin in the short term (∼4 years). The authors suggested that these benefits likely were based on pleiotropic effects, rather than only on antithrombotic action. Indeed, these data confirm a previous suggestion that an anticarcinogenic mechanism of prolonged aspirin use may be related to aspirin-induced chronic iron loss.2
        • Full-Text
        • PDF